	US 12,065,481 B2
	Therapy using a factor XII inhibitor in a neurotraumatic disorder
Christoph Kleinschnitz, Heiligenhaus-Isenbuegel (DE); Marc Nolte, Marburg (DE); Anna-Leena Sirén, Wuerzburg (DE); Christiane Albert-Weissenberger, Bergtheim (DE); and Sarah Hopp-Kraemer, Wuerzburg (DE)
Assigned to CSL BEHRING GMBH, Marburg (DE)
Filed by CSL BEHRING GMBH, Marburg (DE)
Filed on Oct. 29, 2019, as Appl. No. 16/666,886.
Application 16/666,886 is a continuation of application No. 15/318,550, abandoned, previously published as PCT/EP2015/063760, filed on Jun. 18, 2015.
Claims priority of application No. 14172910 (EP), filed on Jun. 18, 2014.
Prior Publication US 2020/0131248 A1, Apr. 30, 2020
Int. Cl. C07K 16/36 (2006.01); A61K 9/00 (2006.01); A61K 31/573 (2006.01); A61K 38/55 (2006.01); A61K 38/57 (2006.01); A61K 39/395 (2006.01); A61K 47/50 (2017.01); C07K 14/76 (2006.01); C07K 14/81 (2006.01); A61K 39/00 (2006.01)

CPC C07K 14/811 (2013.01) [A61K 9/0019 (2013.01); A61K 31/573 (2013.01); A61K 38/55 (2013.01); A61K 38/57 (2013.01); A61K 39/3955 (2013.01); A61K 47/50 (2017.08); C07K 14/76 (2013.01); C07K 14/8135 (2013.01); C07K 16/36 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); C07K 2319/31 (2013.01)]

18 Claims

1. A method of treating a neurotraumatic disorder in a human or animal subject, comprising administering to a subject in need thereof a direct inhibitor of FXII in an amount sufficient to treat microvascular thrombosis in the neurotraumatic disorder, wherein the neurotraumatic disorder resulted from a traumatic injury of the brain of the subject, wherein the inhibitor of FXII is an anti-FXII antibody comprising:

(a) a heavy chain variable region comprising a heavy chain complementarity determining region 1 (HCDR1) sequence of SEQ ID NO: 8, a heavy chain complementarity determining region 2 (HCDR2) sequence of SEQ ID NO: 10, and a heavy chain complementarity determining region 3 (HCDR3) sequence of SEQ ID NO: 11; and

(b) a light chain variable region comprising a light chain complementarity determining region 1 (LCDR1) sequence of SEQ ID NO: 13, a light chain complementarity determining region 2 (LCDR2) sequence of SEQ ID NO: 14, and a light chain complementarity determining region 3 (LCDR3) sequence of SEQ ID NO: 15,

wherein SEQ ID NO: 10 has the sequence GIX₁X₂X₃X₄X₅X₆TVYADSVKG, and X₁is D, X₂is I, X₃is P, X₄is T, X₅is K, and X₆is G.